Upstream Bio (UPB) Cash from Investing Activities (2023 - 2026)

Upstream Bio's Cash from Investing Activities history runs 4 years deep, the most recent figure standing at $42.4 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 119.87% year-over-year to $42.4 million in Q1 2026; TTM through Mar 2026 was $162.3 million, a 156.61% increase from a year earlier, with the FY2025 full-year figure at -$93.5 million, down 57.15% from the prior year.
• Cash from Investing Activities eased to $42.4 million in Q1 2026 per UPB's latest filing, from $58.9 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $58.9 million in Q4 2025 and bottomed at -$213.4 million in Q1 2025.
• The 4-year median for Cash from Investing Activities is $13.3 million (2024), against an average of -$11.6 million.
• Biggest YoY gain for Cash from Investing Activities was 3319.87% in 2025; the steepest drop was 1640.43% in 2025.
• Year by year, Cash from Investing Activities stood at -$5.2 million in 2023, then soared by 899.47% to $41.9 million in 2024, then surged by 40.65% to $58.9 million in 2025, then decreased by 28.06% to $42.4 million in 2026.
• Per Business Quant, the three latest UPB Cash from Investing Activities figures stand at $42.4 million (Q1 2026), $58.9 million (Q4 2025), and $48.2 million (Q3 2025).